Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 6/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | F13A1 | P00488 | 4/20 | 0.39 |
| ▸ | TGM1 | P22735 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.38 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6196618 | 0.85 | USP2 (0.44) | TGM2GPR119USP2SMN1; SMN2F13A1 | |
| SCHEMBL30183473 | 0.83 | USP2 (0.43) | TGM2GPR119USP2SMN1; SMN2F13A1 | |
| SCHEMBL4551353 | 0.83 | USP2 (0.43) | TGM2GPR119USP2SMN1; SMN2GAA | |
| SCHEMBL960091 | 0.83 | GPR119 (0.43) | TGM2GPR119USP2SMN1; SMN2F13A1 | |
| SCHEMBL5214356 | 0.83 | USP2 (0.43) | TGM2GPR119USP2SMN1; SMN2F13A1 | |
| SCHEMBL7527689 | 0.82 | USP2 (0.42) | TGM2GPR119USP2SMN1; SMN2GAA | |
| SCHEMBL2253618 | 0.81 | SMN1; SMN2 (0.46) | TGM2USP2SMN1; SMN2GAAF13A1 | |
| SCHEMBL2249760 | 0.81 | USP2 (0.51) | TGM2USP2SMN1; SMN2GAAF13A1 | |
| SCHEMBL26113743 | 0.80 | USP2 (0.45) | TGM2GPR119USP2SMN1; SMN2F13A1 | |
| Hydrochloric Acid SCHEMBL12501570 | 0.79 | USP2 (0.44) | TGM2GPR119USP2SMN1; SMN2F13A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812446-B1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LTD (GB) | 2015-11-18 | — | — | EP | disclosed |
| US-8697693-B2 | Pharmaceutical compounds | F. Hoffmann LaRoche AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20120283257-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-08 | — | — | US | disclosed |
| US-8252792-B2 | Pyrimidine derivatives as PI3K inhibitors | F. HOFFMAN-LA ROCHE AG (CH) | 2012-08-28 | — | — | US | disclosed |
| US-7872003-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-18 | — | — | US | disclosed |
| US-20100016306-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | US | disclosed |
| EP-2032582-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| US-20080207609-A1 | Pharmaceutical compounds | PLRAMED LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| WO-2007122410-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| EP-1812446-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006046040-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283257-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, PIK3R5 | TGM2 3035/4885GPR119 77/4885USP2 4236/4885 |
| US-20100016306-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | TGM2 2939/4885GPR119 263/4885USP2 3569/4885 |
| US-20080207609-A1 | Pharmaceutical compounds | PIK3CA, JAK2, PIK3R1 | TGM2 3188/4885GPR119 35/4885USP2 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.